21st MEET THE PROFESSOR

Advanced International Breast Cancer Course

Padova | September 11-12, 2025

Presentation

Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 21st AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

  • Gynecologists and obstetrics

  • Medical oncologists

  • Pathologists

  • Radiologists

  • Radiation oncologists

  • Surgeons

  • Biologists

  • Pharmacists

  • Nurses

Scientific Program

Thursday, September 11th

10:30 Introduction to the Conference
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Pierfranco Conte, Aleix Prat

11.00 Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas
Alberto Zambelli
11.20 The immune system and breast cancer: TNBC and beyond
Maria Vittoria Dieci
11.40 DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer
Mafalda Oliveira
12.00 Tackling the biological diversity in HER2-positive breast cancer: clinical implications
Aleix Prat
12.20 Discussion
12.50 Lunch
SESSION II – GENETIC PREDISPOSITION TO BREAST CANCER

Chairpersons: Bettina Borisch, Fedro Peccatori

14.00 Genetic testing beyond BRCA
Teresa Ramon y Cajal
14.20 Challenges in locoregional treatments:

  • the surgeon’s view – Eleftherios Mamounas
  • the radiation oncologist’s view – Jacek Jassem
  • the patient’s view point – Bettina Borisch
15.00 Systemic treatment options in patients with genetic predisposition with Early and Advanced disease
Sandra Swan
15.30 Discussion
16.00 Coffee break
SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY

Chairpersons: Giuseppe Curigliano, Sibylle Loibl

16.20 Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+
Sibylle Loibl
16.40 Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC
Hope Rugo
17.00 Neoadjuvant Treatment in HR+HER2-BC: why, when, which one
Valentina Guarneri
17.20 Response-guided radiotherapy after neoadjuvant treatments
Angel Montero Luis
17.40 Discussion
18.00 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2025
18.15 Lecture of the Awardee
18.45 Adjourn

Friday, September 12th

SESSION IV – EARLY BREAST CANCER

Chairpersons: Lucia del Mastro, Michelino De Laurentiis

9.00 Enhancing efficacy of hormonal therapy in early breast cancer
Stephen Johnston
9.20 Adjuvant treatments for rare histologies: how to manage uncertainty
Valentina Guarneri
9.40 Life style intervention after breast cancer
Claudio Vernieri
10.00 Discussion
10.30 Coffee break
11.00 Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer
Panelist: Lucia Del Mastro, Michelino De Laurentiis, Hesham Ahmed Gaballah Elghazaly, Stephen Johnston, Eleftherios Mamounas, Philip Poortmans, Hope Rugo, Sandra Swain
12.30 Lunch
SESSION V – METASTATIC BREAST CANCER: STATE OF ART AND TRIALS LIKELY TO IMPACT IN THE FUTURE

Chairpersons: Alessandra Gennari, Fabio Puglisi

13.30 HR+ disease
Laura Biganzoli
14.00 HER2+ disease
Giuseppe Curigliano
14.30 Triple negative disease
Giampaolo Bianchini
15.00 Discussion
15.20 Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer
Panelist: Hesham Ahmed Gaballah Elghazaly , Alessandra Gennari, Jacek Jassem, Stephen Johnston, Eleftherios Mamounas, Fabio Puglisi, Sandra Swain, Hope Rugo
16.40 Take home messages and adjourn
Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-419161): 12 CME points.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

To obtain CME credits, participants must meet the following requirements:

  • Their declared profession/specialization must correspond to those accredited for CME;
  • They must attend at least 90% of the course;
  • They must complete the online meeting evaluation form;
  • They must pass the learning assesment test with at least 75% correct answers. Only one attempt is allowed.

The learning assessment test and meeting evaluation form must be submitted within three days of the event.

Open in Google Maps

Meeting Venue

Palazzo della Salute
Via San Francesco, 90 – Padua

The Center is located in the ZTL area. We recommend the Interparking Italia – Via Trieste 50.

Open in Google Maps

Award & Fellowships

University of Padova Award for advances in breast cancer 2025

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The Scientific Commitee will select the final winner which will be invited to present his/her study during the annual Conference.

Fellowships

Some fellowship (for under 40) will be awarded including registration, 1 hotel night and reimbursement of travel expenses (max of travel reimbursement 200,00). Those interested should send the registration form together with a short CV and a motivation letter within September 1st.
The organizing secretariat will confirm the award of the fellowship within September 5th and proceed with the organization of logistics.

Under 40

Free admission is available for some people “under 40”. Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.

Faculty

Directors

Pierfranco Conte
Pierfranco ConteVenezia (IT)
Scientific Director S. Camillo Hospital, IRCCS, Venezia (IT)
Valentina Guarneri
Valentina GuarneriPadova (IT)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology, University of Padova (IT)
Philip Poortmans
Philip PoortmansWilrijk-Antwerp (BE)
Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Netwerk
University of Antwerp (BE)
Aleix Prat
Aleix PratBarcellona (ES)
Clinic Barcelona Comprehensive Cancer Center
University of Barcelona – Barcelona (ES)

Scientific Committee

Bettina Borisch
Institute of Global Health
Geneve (CH)

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
Padova (IT)

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl
German Breast Group
University of Frankfurt (DE)

Eleftherios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (US)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (IT)

Sandra M. Swain
Professor of Medicine, Associate Dean Research Development
Georgetown University Medical Center
Washington (US)

Speakers

Giampaolo Bianchini
Milano (IT)

Laura Biganzoli
Prato (IT)

Giuseppe Curigliano
University of Milano (IT)

Michelino De Laurentiis
Napoli (IT)

Lucia Del Mastro
Genova (IT)

Alesssandra Gennari
Novara (IT)

Angel Montero Luis
Madrid (ES)

Mafalda Oliveira
Barcellona (ES)

Fabio Puglisi
Aviano (IT)

Hope Rugo
San Francisco (US)

Teresa Ramon j Cajal
Barcelona (ES)

Claudio Vernieri
Milano (IT)

Alberto Zambelli
Bergamo (IT)

Download all the slides of AIBCC 2024.

With the patronage of

INSTITUTIONS

SCIENTIFIC SOCIETIES